Security Snapshot

KRANESHARES TRUST - QUADRTC INT RT (IVOL) Institutional Ownership

CUSIP: 500767736

13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

77

Shares (Excl. Options)

14,083,576

Price

$18.71

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / QUADRTC INT RT
Symbol
IVOL
Price per share
$18.29
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
14,083,576
Total reported value
$263,370,980
% of total 13F portfolios
0%
Share change
+819,380
Value change
+$14,915,369
Number of holders
77
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Key facts

  • IVOL - KRANESHARES TRUST - QUADRTC INT RT is tracked under CUSIP 500767736.
  • 77 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 90 to 77 between Q4 2025 and Q1 2026.
  • Reported value moved from $254,563,246 to $263,370,980.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 77 institutions filings for Q1 2026.

Open SEC Evidence

Security key

500767736

Latest holder period

Q1 2026

13F holders

77

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 77 institutional investors reported holding 14,083,576 shares of KRANESHARES TRUST - QUADRTC INT RT (IVOL).

Institutional Holders of KRANESHARES TRUST - QUADRTC INT RT (IVOL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 14,083,576 $263,370,980 +$14,915,369 $18.71 77
2025 Q4 13,295,893 $254,563,246 +$66,205,786 $19.16 90
2025 Q3 9,697,616 $187,069,795 +$61,219,472 $19.28 89
2025 Q2 6,524,107 $127,385,197 -$186,683,029 $19.56 72
2025 Q1 15,927,057 $297,627,753 +$287,394 $18.68 86
2024 Q4 16,032,671 $284,468,716 -$94,575,982 $17.74 102
2024 Q3 21,089,027 $407,472,733 +$26,280,719 $19.25 122
2024 Q2 19,805,549 $366,649,290 -$120,638,366 $18.51 114
2024 Q1 26,273,102 $497,199,670 -$30,145,947 $18.93 118
2023 Q4 28,527,441 $589,488,819 +$8,906,272 $20.68 139
2023 Q3 27,947,271 $574,681,320 +$139,481,232 $20.56 138
2023 Q2 21,171,800 $436,217,036 +$85,756,196 $20.58 131
2023 Q1 17,265,700 $393,500,818 -$161,034,483 $22.72 136
2022 Q4 25,039,575 $566,800,048 -$50,146,002 $22.61 156
2022 Q3 26,659,273 $593,443,180 -$272,919,823 $22.16 168
2022 Q2 37,857,287 $959,518,170 +$5,178,675 $25.34 190
2022 Q1 39,837,772 $1,017,779,164 -$426,930,989 $25.62 196
2021 Q4 54,197,260 $1,454,589,390 -$647,759,200 $26.85 217
2021 Q3 77,643,133 $2,162,841,253 -$9,570,795 $27.87 238
2021 Q2 76,919,590 $2,125,137,876 +$662,389,502 $27.62 239
2021 Q1 51,751,590 $1,478,962,832 +$1,045,374,631 $28.58 219
2020 Q4 14,406,750 $403,691,313 +$175,693,653 $27.97 104
2020 Q3 8,049,462 $220,714,500 +$131,808,518 $27.42 71
2020 Q2 2,395,722 $65,003,516 +$47,970,550 $27.14 29
2020 Q1 631,201 $16,327,573 +$5,736,431 $25.82 14
2019 Q4 410,277 $10,392,088 -$388,082 $25.31 11
2019 Q3 425,321 $10,817,793 +$3,413,954 $25.42 9
2019 Q2 291,002 $7,564,000 +$7,458,000 $25.97 3
2019 Q1 3,852 $106,000 $27.52 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .